This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Euclises Pharmaceuticals, Inc.
Drug Names(s): ECP1014, ECP 1014, GIBH-1014, GIBH1014, GIBH 1014
Description: ECP-1014 is a cyclooxygenase-2 (COX-2) inhibitor, developed using its proprietary Euclicoxib platform.
Euclises and Guangzhou Institutes of Biomedicine and Health (GIBH)
In December 2014, Euclises Pharmaceuticals announced an agreement with Guangzhou Institutes of Biomedicine and Health (GIBH), focused on accelerating the development of both Euclises and GIBHs COX-2 inhibitors. With the agreement, Euclises adds COX-2 inhibitors (coxibs) discovered and currently under development by GIBH, including the advanced preclinical candidate GIBH-1014, to its Euclicoxib pipeline. GIBH and Euclises will also collaborate extensively on the further development of Euclicoxib candidates, particularly for the treatment of cancers driven by COX-2 and prostaglandin E2 (PGE2). Euclises and GIBH will jointly complete selection of one or more clinical candidates. Thereafter, Euclises will be responsible for global clinical development in cancer, while GIBH will take the lead in China for pain and inflammation indications.
Additional information available to subscribers only: